lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy
metachromatic leukodystrophy mld inherited lysosomal storage disease caused arylsulfatase arsa deficiency patients mld exhibit progressive motor cognitive impairment die within years symptom onset used lentiviral vector transfer functional arsa gene hematopoietic stem cells hscs three presymptomatic patients showed genetic biochemical neurophysiological evidence late infantile mld reinfusion gene-corrected hscs patients showed extensive stable arsa gene replacement led high enzyme expression throughout hematopoietic lineages cerebrospinal fluid analyses vector integrations revealed evidence aberrant clonal behavior disease manifest progress three patients months beyond predicted age symptom onset findings indicate extensive genetic engineering human hematopoiesis can achieved lentiviral vectors approach may offer therapeutic benefit mld patients
